These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21106730)

  • 1. Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.
    Crescenzi M; Persano L; Esposito G; Zulato E; Borsi L; Balza E; Ruol A; Ancona E; Indraccolo S; Amadori A
    Clin Cancer Res; 2011 Feb; 17(3):447-58. PubMed ID: 21106730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeted delivery of TNFalpha to tumor blood vessels.
    Borsi L; Balza E; Carnemolla B; Sassi F; Castellani P; Berndt A; Kosmehl H; Biro A; Siri A; Orecchia P; Grassi J; Neri D; Zardi L
    Blood; 2003 Dec; 102(13):4384-92. PubMed ID: 12933583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.
    Langenkamp E; Zwiers PJ; Moorlag HE; Leenders WP; St Croix B; Molema G
    Anticancer Drugs; 2012 Feb; 23(2):161-72. PubMed ID: 22075979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin.
    Balza E; Mortara L; Sassi F; Monteghirfo S; Carnemolla B; Castellani P; Neri D; Accolla RS; Zardi L; Borsi L
    Clin Cancer Res; 2006 Apr; 12(8):2575-82. PubMed ID: 16638868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.
    Hatem R; Labiod D; Château-Joubert S; de Plater L; El Botty R; Vacher S; Bonin F; Servely JL; Dieras V; Bièche I; Marangoni E
    Int J Cancer; 2016 May; 138(10):2510-21. PubMed ID: 26686064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
    Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
    Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
    Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
    Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
    Naumov GN; Nilsson MB; Cascone T; Briggs A; Straume O; Akslen LA; Lifshits E; Byers LA; Xu L; Wu HK; Jänne P; Kobayashi S; Halmos B; Tenen D; Tang XM; Engelman J; Yeap B; Folkman J; Johnson BE; Heymach JV
    Clin Cancer Res; 2009 May; 15(10):3484-94. PubMed ID: 19447865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
    Ogino H; Yano S; Kakiuchi S; Yamada T; Ikuta K; Nakataki E; Goto H; Hanibuchi M; Nishioka Y; Ryan A; Sone S
    Cancer Lett; 2008 Jun; 265(1):55-66. PubMed ID: 18364248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.
    Sasaki T; Tanno S; Shibukawa K; Osanai S; Kawabe J; Ohsaki Y
    Int J Oncol; 2008 Sep; 33(3):525-32. PubMed ID: 18695882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
    Wachsberger PR; Lawrence YR; Liu Y; Daroczi B; Xu X; Dicker AP
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):483-91. PubMed ID: 21095630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.
    Siegfried JM; Gubish CT; Rothstein ME; Henry C; Stabile LP
    J Thorac Oncol; 2012 Mar; 7(3):485-95. PubMed ID: 22258476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.
    Sathornsumetee S; Rich JN
    Drugs Today (Barc); 2006 Oct; 42(10):657-70. PubMed ID: 17136225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.
    Balza E; Carnemolla B; Mortara L; Castellani P; Soncini D; Accolla RS; Borsi L
    Int J Cancer; 2010 Jul; 127(1):101-10. PubMed ID: 19877124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.
    Zage PE; Zeng L; Palla S; Fang W; Nilsson MB; Heymach JV; Zweidler-McKay PA
    Cancer; 2010 May; 116(10):2465-75. PubMed ID: 20225331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
    Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
    J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.